Document Detail

Safety and efficacy of tenecteplase in acute myocardial infarction.
MedLine Citation:
PMID:  12740001     Owner:  NLM     Status:  MEDLINE    
The use of intravenous thrombolytic agents has revolutionised the treatment of acute myocardial infarction. However, the improved mortality achieved with these drugs is tempered by the risk of serious bleeding complications, especially intracranial haemorrhage (ICH). Tenecteplase (TNKase, Genetech Inc.) is an engineered variant of alteplase (Activase, Genentech Inc.) designed to have increased fibrin specificity, greater efficacy and a longer half-life. The longer half-life of tenecteplase compared to alteplase allows for convenient single bolus administration of the drug. In addition, tenecteplase dosing is based on actual or estimated patient weight, which enhances both the safety and efficacy outcomes. Large clinical trials have demonstrated equivalence in mortality and ICH between tenecteplase and alteplase. Compared to alteplase, tenecteplase use leads to lower rates of bleeding complications and a decreased risk of ICH among low weight, elderly women.
Daniel R Guerra; Juhana Karha; C Michael Gibson
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Expert opinion on pharmacotherapy     Volume:  4     ISSN:  1465-6566     ISO Abbreviation:  Expert Opin Pharmacother     Publication Date:  2003 May 
Date Detail:
Created Date:  2003-05-12     Completed Date:  2003-07-22     Revised Date:  2008-04-14    
Medline Journal Info:
Nlm Unique ID:  100897346     Medline TA:  Expert Opin Pharmacother     Country:  England    
Other Details:
Languages:  eng     Pagination:  791-8     Citation Subset:  IM    
Department of Medicine, Brigham Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Area Under Curve
Body Weight
Fibrinolytic Agents / pharmacokinetics,  pharmacology,  therapeutic use*
Metabolic Clearance Rate
Myocardial Infarction / drug therapy*
Randomized Controlled Trials as Topic
Tissue Plasminogen Activator / pharmacokinetics,  pharmacology,  therapeutic use*
Reg. No./Substance:
0/Fibrinolytic Agents; 0/tenecteplase; EC Plasminogen Activator

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Colesevelam HCl: a non-systemic lipid-altering drug.
Next Document:  Zanamivir in the treatment of influenza.